TSH receptor antibody
EstablishedTRAb, specifically the stimulating TSI form, is the direct cause of and diagnostic marker for Graves' disease.
This antibody directly causes Graves' disease by overstimulating the thyroid. Testing for it confirms Graves' as the specific cause of an overactive thyroid, and during pregnancy, it's especially important to check since these antibodies can cross into the baby and affect the baby's thyroid too.
TSH receptor antibodies (TRAb) target the TSH receptor on thyroid cells; stimulating variants of this antibody are the direct cause of Graves' disease, the most common cause of hyperthyroidism.
Positive TRAb (specifically thyroid-stimulating immunoglobulin, TSI) confirms Graves' disease as the cause of hyperthyroidism, distinguishing it from other causes like toxic nodular goiter or thyroiditis, which don't involve this antibody.
Measured via immunoassay, either as a functional bioassay (measuring actual receptor-stimulating activity, more specific) or a binding assay (measuring antibody presence without confirming functional activity); the functional TSI assay is generally preferred when available given its higher specificity for Graves' disease.
TRAb levels help predict relapse risk after antithyroid drug treatment is stopped and are essential during pregnancy, since these antibodies cross the placenta and can cause fetal or neonatal hyperthyroidism (a distinct clinical concern from the SS-A/Ro antibody-related congenital heart block discussed elsewhere in this biomarker set, though both involve antibodies crossing into the fetus).
Crosses the placenta during pregnancy, requiring monitoring to prevent fetal or neonatal hyperthyroidism.
- General endocrinology reference literature on TSH receptor antibody in Graves' disease diagnosis and pregnancy management.